Cover Image
市場調查報告書

DNAVEC Corporation- 產品平台檢討

DNAVEC Corporation - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 332894
出版日期 內容資訊 英文 25 Pages
訂單完成後即時交付
價格
Back to Top
DNAVEC Corporation- 產品平台檢討 DNAVEC Corporation - Product Pipeline Review - 2015
出版日期: 2015年05月13日 內容資訊: 英文 25 Pages
簡介

DNAVEC Corporation是總公司設立於日本的製藥企業,正從事基因治療藥的開發及商品化,加上再生醫藥品·細胞治療藥等生物商務之開發。利用仙台病毒載體這個媒介平台,分析基因治療藥,遺傳基因疫苗,抗體,蛋白質製造,遺傳基因之功能分析,其對象領域有心血管系統疾病,呼吸疾病,自體免疫疾病,眼科疾病,癌症。

本報告提供DNAVEC Corporation的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

DNAVEC Corporation的基本資料

  • DNAVEC Corporation概要
  • 主要資訊
  • 企業資料

DNAVEC Corporation:R&D概要

  • 主要的治療範圍

DNAVEC Corporation:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

DNAVEC Corporation:開發中產品概況

  • 臨床階段的開發中產品
    • 第Ⅱ相的產品/聯合治療模式
    • 第Ⅰ相的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

DNAVEC Corporation:藥物簡介

  • DVC1-0101
  • Gene Therapy for Glaucoma and Retinitis Pigmentosa
  • SeV-G

DNAVEC Corporation:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

DNAVEC Corporation:最近的開發平台資訊

DNAVEC Corporation:總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

目錄
Product Code: GMDHC07091CDB

Summary

Global Markets Direct's, 'DNAVEC Corporation - Product Pipeline Review - 2015', provides an overview of the DNAVEC Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of DNAVEC Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of DNAVEC Corporation including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of DNAVEC Corporation's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the DNAVEC Corporation's pipeline products

Reasons to buy

  • Evaluate DNAVEC Corporation's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of DNAVEC Corporation in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the DNAVEC Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of DNAVEC Corporation and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of DNAVEC Corporation
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of DNAVEC Corporation and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • DNAVEC Corporation Snapshot
    • DNAVEC Corporation Overview
    • Key Information
  • Key Facts
  • DNAVEC Corporation - Research and Development Overview
  • Key Therapeutic Areas
  • DNAVEC Corporation - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • DNAVEC Corporation - Pipeline Products Glance
    • DNAVEC Corporation - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • DNAVEC Corporation - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • DNAVEC Corporation - Drug Profiles
    • DVC1-0101
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy for Glaucoma and Retinitis Pigmentosa
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SeV-G
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • DNAVEC Corporation - Pipeline Analysis
    • DNAVEC Corporation - Pipeline Products by Target
    • DNAVEC Corporation - Pipeline Products by Route of Administration
    • DNAVEC Corporation - Pipeline Products by Molecule Type
    • DNAVEC Corporation - Pipeline Products by Mechanism of Action
  • DNAVEC Corporation - Recent Pipeline Updates
  • DNAVEC Corporation - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • DNAVEC Corporation, Key Information
  • DNAVEC Corporation, Key Facts
  • DNAVEC Corporation - Pipeline by Indication, 2015
  • DNAVEC Corporation - Pipeline by Stage of Development, 2015
  • DNAVEC Corporation - Monotherapy Products in Pipeline, 2015
  • DNAVEC Corporation - Partnered Products in Pipeline, 2015
  • DNAVEC Corporation - Partnered Products/ Combination Treatment Modalities, 2015
  • DNAVEC Corporation - Phase II, 2015
  • DNAVEC Corporation - Phase I, 2015
  • DNAVEC Corporation - Preclinical, 2015
  • DNAVEC Corporation - Pipeline by Target, 2015
  • DNAVEC Corporation - Pipeline by Route of Administration, 2015
  • DNAVEC Corporation - Pipeline by Molecule Type, 2015
  • DNAVEC Corporation - Pipeline Products by Mechanism of Action, 2015
  • DNAVEC Corporation - Recent Pipeline Updates, 2015

List of Figures

  • DNAVEC Corporation - Pipeline by Top 10 Indication, 2015
  • DNAVEC Corporation - Pipeline by Stage of Development, 2015
  • DNAVEC Corporation - Monotherapy Products in Pipeline, 2015
  • DNAVEC Corporation - Partnered Products in Pipeline, 2015
  • DNAVEC Corporation - Pipeline by Top 10 Target, 2015
  • DNAVEC Corporation - Pipeline by Top 10 Route of Administration, 2015
  • DNAVEC Corporation - Pipeline by Top 10 Molecule Type, 2015
  • DNAVEC Corporation - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top